September 2012, Biodesy gives a talk at the FBLD 2012 conference in San Francisco
The focus of the presentation was the use of the Biodesy platform to identify allosteric and conformation-specific ligands with X-ray sensitivity, under physiological conditions and in real time.
August 2012, Prof. Frank McCormick joins the Biodesy Advisory Board
Dr. McCormick is the Director of the Helen Diller Cancer Center at the University of California, San Francisco (UCSF), Associate Dean of the School of Medicine at UCSF, and the President of the American Association for Cancer Research (AACR). He is a world leader in research involving the protein Ras and its signaling pathway. Mutated Ras, found in 30% of human cancers, was discovered three decades ago and is considered 'undruggable' using conventional drug discovery technologies. Dr. McCormick is also the founder of Onyx Pharmaceuticals.
June 2012, Biodesy receives Phase IB award from the National Science Foundation (NSF)
The award was made to further the development of the ArtemisTM platform, comprising hardware, software, and wetware.
April 2012, Biodesy present data at the World Molecular Engineering (WMEN) Conference by invitation in Cabo, Mexico
The title of the presentation was ‘Second-harmonic generation (SHG) for allosteric drug discovery: conformational change in real time’
February 2012, Roche scientists present SHG collaboration data on evaluation of 2 proteins
Roche scientists recently presented a poster at the first annual Society for Laboratory Automation and Screening (SLAS) using data from a collaboration with Biodesy on the use of SHG to identify conformation change in 2 un-named proteins using a series of ligands. Data collected using SHG accurately identified active and non-active compounds and provided measurements that were in agreement with X-ray crystallography and Biacore studies. A copy of the poster, ‘Assaying protein conformational change in real time – A novel approach for target-based drug discovery’ can be found here.
February 2012, Biodesy present recent SHG data at 1st annual Society for Laboratory Automation and Screening (SLAS) Conference
Biodesy recently presented an update on its SHG platform and related applications at the just completed SLAS conference. The title of the presentation was ‘Real-time measurement of protein conformational change in key therapeutic targets: application to Abl kinase and mutant Ras’. Included in this presentation was Biodesy’s recent work demonstrating the use of SHG to measure conformational changes to putative allosteric modulators in the key therapeutic target H-Ras.
November 2011, Biodesy awarded prestigious grant from the National Science Foundation (NSF)
Biodesy announce their receipt of a Phase I Small Business Innovation Research (SBIR ) grant from the National Science Foundation. This grant was awarded to further Biodesy’s work on its revolutionary SHG platform to advance the understanding of the conformational changes that occur in the key therapeutic protein kinase, Abl kinase, in response to type-I and type-II inhibitors. According to the NSF, fewer than 10% of grant proposals were funded in 2011.
March 2011, Biodesy Present Data at 17th Annual SBS Conference: Poster voted in the top 10 at the conference
Biodesy recently presented two posters at the 17th annual SBS conference In Orlando, Florida
Our poster demonstrating the ability of SHG to identify characteristic responses of type-II kinase inhibitors of the therapeutically relevant protein kinase, Abl-kinase, was voted amongst the top 10 poster presentations at the conference. To download a copy of this and the second poster, please click the links above.
November 2010, Biodesy awarded a Qualifying Therapeutic Discovery Project (QTDP) grant
Biodesy has been awarded a QTDP grant for its program in Parkinson’s disease. This grant provides funds to further the development of therapeutics targeted to alpha-synuclein for Parkinson’s disease using our unique SHG technology.
October 2010, Biodesy to present at the upcoming Parkinson’s Therapeutic conference organized by the Michael J Fox Foundation
Biodesy will present its latest advances on Parkinson’s research using SHG detection.
